Aspiriant LLC Makes New $319,000 Investment in GSK PLC Sponsored ADR (NYSE:GSK)

Aspiriant LLC acquired a new stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 8,241 shares of the pharmaceutical company's stock, valued at approximately $319,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GSK. FMR LLC increased its holdings in shares of GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock worth $1,786,475,000 after acquiring an additional 23,814,104 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of GSK by 70.1% in the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock worth $854,349,000 after acquiring an additional 10,407,905 shares in the last quarter. Voloridge Investment Management LLC increased its holdings in shares of GSK by 1,360.4% in the fourth quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock worth $73,222,000 after acquiring an additional 2,016,795 shares in the last quarter. Bridgewater Associates LP increased its holdings in shares of GSK by 132.7% in the fourth quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company's stock worth $76,017,000 after acquiring an additional 1,281,855 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in shares of GSK in the fourth quarter worth about $36,665,000. Institutional investors own 15.74% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on GSK. Wall Street Zen downgraded GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. BNP Paribas began coverage on GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target for the company. Berenberg Bank restated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, Hsbc Global Res raised GSK to a "strong sell" rating in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $37.38.

GSK Stock Down 1.7%

NYSE GSK traded down $0.65 during trading hours on Friday, hitting $37.99. 8,245,796 shares of the company traded hands, compared to its average volume of 4,933,992. The business's 50-day moving average is $38.51 and its 200-day moving average is $36.79. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.67. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87. The stock has a market capitalization of $77.79 billion, a price-to-earnings ratio of 19.58, a P/E/G ratio of 1.35 and a beta of 0.52.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The company had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. During the same period last year, the firm posted $0.43 earnings per share. The business's revenue was up 2.1% on a year-over-year basis. Sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.44%. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. GSK's dividend payout ratio (DPR) is presently 87.11%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.